Because AMPK activation is central to the protective activity of 3C in atherosclerosis, the AMPK-STAT1-STING pathway may be a valid pharmacological target for treating inflammation-related diseases such as atherosclerosis, insulin resistance, and cardiovascular disease. Here, PRKAA1 is linked to Insulin resistance.